BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12843186)

  • 1. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
    Park JW; Yeh MW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3346-53. PubMed ID: 12843186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
    Hoelting T; Siperstein AE; Clark OH; Duh QY
    J Clin Endocrinol Metab; 1994 Aug; 79(2):401-8. PubMed ID: 8045955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M; Liu F; Tavorath R; Rosen N
    Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase.
    Stancato LF; Silverstein AM; Owens-Grillo JK; Chow YH; Jove R; Pratt WB
    J Biol Chem; 1997 Feb; 272(7):4013-20. PubMed ID: 9020108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels.
    Braga-Basaria M; Hardy E; Gottfried R; Burman KD; Saji M; Ringel MD
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2982-8. PubMed ID: 15181088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
    Ochel HJ; Eichhorn K; Gademann G
    Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
    [No Abstract]   [Full Text] [Related]  

  • 11. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
    An WG; Schnur RC; Neckers L; Blagosklonny MV
    Cancer Chemother Pharmacol; 1997; 40(1):60-4. PubMed ID: 9137531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG; Matts RL
    Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin.
    Sugita T; Tanaka S; Murakami T; Miyoshi H; Ohnuki T
    Biochem Mol Biol Int; 1999 Apr; 47(4):587-95. PubMed ID: 10319410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines.
    Hölting T; Zielke A; Siperstein AE; Clark OH; Duh QY
    J Clin Endocrinol Metab; 1994 Sep; 79(3):806-13. PubMed ID: 8077365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
    Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR; Bradley MS; Jin X; Lin J
    Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.